pneumonia
defin
acut
respiratori
infect
affect
lung
parenchyma
despit
avail
antibiot
therapi
sever
ill
assess
pneumonia
continu
lead
caus
death
worldwid
elderli
popul
impact
pneumonia
greater
age
group
mechan
increas
incid
mortal
rate
elderli
pneumonia
patient
fulli
understood
immunolog
chang
call
immunosenesc
known
respons
increas
sensit
elderli
peopl
infect
diseas
world
popul
reach
billion
peopl
year
amount
total
million
accord
data
unit
nation
world
popul
prospect
kaplan
et
al
annual
incid
pneumonia
elderli
fourtim
younger
popul
older
adult
also
higher
rate
hospit
mortal
chong
street
therefor
better
understand
pathophysiolog
microbiolog
treatment
prevent
common
afflict
requir
proper
diagnosi
treatment
advic
pneumonia
classifi
communityacquir
pneumonia
cap
hospitalacquir
pneumonia
hap
ventilatorassoci
pneumonia
vap
along
recent
guidelin
section
recent
data
regard
epidemiolog
microbiolog
diagnosi
classif
treatment
prevent
strategi
present
incid
pneumonia
vari
accord
geograph
locat
healthcar
set
popul
includ
pneumonia
lower
respiratori
tract
infect
fourth
common
caus
death
world
studi
carri
us
annual
incid
pneumonia
observ
adult
highest
rate
among
adult
year
age
adult
patient
year
old
adult
konomura
et
al
term
econom
impact
two
studi
carri
netherland
japan
sustain
remark
result
major
cap
episod
occur
among
patient
year
older
episod
incur
cost
second
studi
includ
patient
cap
age
year
report
median
treatment
cost
us
per
outpati
cap
us
per
hospit
cap
klausen
et
al
koth
et
al
mortal
elderli
patient
may
higher
gener
popul
popul
group
hospit
rate
five
time
like
patient
group
also
chong
street
neg
impact
sever
studi
attempt
identifi
risk
factor
populationbas
cohort
studi
elderli
patient
found
immunosuppress
copd
smoke
congest
heart
failur
diabet
malign
previou
hospit
pneumonia
independ
risk
factor
develop
diseas
age
group
barlow
et
al
mortal
risk
avail
data
use
comorbid
ill
includ
cerebrovascular
diseas
congest
heart
failur
chronic
liver
diseas
higher
infect
activ
index
ineffect
therapi
present
along
higher
mortal
risk
elderli
factor
link
increas
mortal
accept
bedridden
statu
delirium
absenc
fever
tachypnea
creactiv
protein
level
greater
mgl
hypoalbuminemia
acut
organ
failur
suspicion
aspir
swallow
disord
center
diseas
control
prevent
cdc
identifi
caus
agent
use
guid
antimicrobi
therapi
although
microbiolog
diagnosi
fundament
ensur
appropri
therapi
achiev
less
case
order
avoid
delay
associ
increas
mortal
antimicrobi
therapi
administ
empir
pathogen
associ
communityacquir
pneumonia
elderli
patient
present
tabl
age
group
possibl
obtain
diagnost
sputum
sampl
low
caus
organ
identifi
case
global
pneumonia
accept
common
pathogen
also
elderli
microorgan
remain
singl
common
organ
identifi
hospit
patient
diagnosi
pneumococc
pneumonia
increas
recent
year
due
introduct
pneumococc
urin
antigen
test
incid
probabl
decreas
pneumococc
vaccin
along
decreas
rate
smoke
garcia
vidal
et
al
differ
chemic
antigen
composit
pneumococc
capsul
result
differ
serotyp
serotyp
common
serotyp
associ
adult
pneumococc
infect
septic
shock
cilloniz
et
al
haemophilu
influenza
also
frequent
isol
account
elderli
patient
chronic
obstruct
lung
diseas
infect
organ
may
common
moraxella
catarrhali
staphylococcu
aureu
methicillin
sensit
also
describ
pathogen
frequenc
respect
cdc
intracellular
pathogen
one
frequent
microorgan
donowitz
cox
incid
variabl
depend
difficulti
microbiolog
cultur
grow
poorli
standard
cultur
media
perform
addit
serolog
test
patient
common
practic
legionella
pneumophila
mycoplasma
pneumonia
chlamydophila
pneumonia
chlamydophila
psittaci
coxiella
burnetii
wellestablish
intracellular
pathogen
clinic
featur
exist
make
possibl
distinguish
intracellular
pathogen
classic
one
extrapulmonari
manifest
often
associ
intracellular
pathogen
sever
pneumonia
caus
pathogen
account
case
major
problem
pathogen
antibiot
unabl
access
intracellular
space
reach
optim
therapeut
concentr
difficult
age
year
atyp
organ
less
frequent
encount
play
signific
role
clinic
spectrum
macfarlan
et
al
chlamydophila
pneumonia
common
rate
mycoplasma
pneumonia
less
frequent
encount
coxiella
burnetii
rare
caus
agent
elderli
cdc
although
legionella
pneumophila
rel
uncommon
elderli
consid
present
atyp
symptom
exampl
headach
alter
mental
statu
gastrointestin
sign
bradycardia
ruuskanen
et
al
appear
reason
exclud
bacteria
urinari
antigen
test
elderli
patient
pneumonia
atyp
coverag
discontinu
infect
gramneg
bacteria
often
relat
comorbid
ill
exclud
nursinghom
resid
hospit
patient
infect
infrequ
elderli
sever
debilit
chronic
ill
elderli
patient
commun
especi
fail
improv
standard
therapi
high
index
suspicion
may
warrant
bacteria
cdc
among
pathogen
respiratori
virus
consid
respons
onethird
case
influenza
virus
b
respiratori
syncyti
viru
rsv
parainfluenza
virus
coronavirus
rhinovirus
commonli
encount
one
estim
million
case
viral
pneumonia
occur
annual
ruuskanen
et
al
influenza
viru
b
usual
selflimit
sever
complic
like
pneumonia
occur
especi
highrisk
patient
like
elderli
comorbid
along
increas
mortal
risk
routin
influenza
screen
appear
reason
elderli
present
pneumonialik
complaint
sensit
avail
screen
test
poor
treatment
decis
base
result
rapid
flu
test
aspir
pneumonia
anoth
common
caus
cap
frequent
microorgan
anaerob
bacteria
microaerophil
streptococci
oral
flora
aspir
pneumonia
may
second
common
etiolog
cap
patient
year
older
teramoto
et
al
approxim
cap
case
multidrugresist
mdr
resist
three
class
antibioticspathogen
agent
frequent
aureu
p
aeruginosa
recent
european
studi
mdr
pathogen
present
cap
case
commonli
present
methicillinresist
aureu
mrsa
communityassoci
methicillinresist
aureu
camrsa
rais
concern
infect
elderli
adult
product
toxin
pantonvalentin
leukocidin
pvl
main
characterist
camrsa
toxin
caus
leukocyt
destruct
tissu
necrosi
elderli
camrsa
consid
present
influenza
prodrom
skin
lesion
cavitari
infiltr
hemoptysi
rapidli
progress
pneumonia
tabl
pathogen
associ
communityacquir
pneumonia
elderli
patient
pseudomona
aeruginosa
endem
opportunist
infect
p
aeruginosa
frequent
pathogen
cap
sever
cap
requir
intens
care
unit
icu
admiss
caus
agent
case
mortal
rate
yoshimoto
et
al
prior
antibiot
treatment
risk
factor
associ
cap
caus
mdr
p
aeruginosa
also
pneumonia
increas
resist
sever
antibiot
cephalosporin
macrolid
fluoroquinolon
last
two
decad
pneumococcu
diseas
case
worldwid
mdr
pattern
nevertheless
therapeut
failur
involv
blactam
report
pharmacodynam
properti
draghi
et
al
hap
defin
pneumonia
occur
h
hospit
admiss
vap
defin
pneumonia
occur
h
endotrach
intub
hap
second
frequent
nosocomi
infect
consid
main
caus
mortal
nosocomi
infect
vap
consid
main
nosocomi
infect
icu
hap
divid
two
group
accord
time
onset
admiss
earli
onset
defin
pneumonia
develop
within
first
day
hospit
present
associ
better
clinic
prognosi
late
onset
defin
pneumonia
occur
day
hospit
recent
publish
guidelin
propos
presenc
risk
factor
mdr
take
preced
rather
earli
late
onset
pneumonia
distinct
kalil
et
al
top
six
pathogen
caus
hap
case
aureu
p
aeruginosa
klebsiella
spp
escherichia
coli
acinetobact
spp
enterobact
spp
tabl
gramneg
bacteria
major
agent
hap
case
icu
frequent
pathogen
includ
p
aeruginosa
baumannii
h
influenza
enterobacteriacea
spp
k
pneumonia
e
coli
enterobact
speci
serratia
speci
proteu
speci
etc
mortal
increas
advanc
age
increas
diseas
score
inadequ
initi
antimicrobi
treatment
independ
factor
predict
mortal
use
vasopressor
case
vap
p
aeruginosa
isol
micek
et
al
gramposit
pathogen
account
hap
case
frequent
microorgan
methicillinresist
methicillinsensit
aureu
pneumonia
streptococcu
spp
pneumonia
caus
two
pathogen
microorgan
defin
polymicrobi
infect
approxim
vap
case
consid
polymicrobi
etiolog
polymicrobi
etiolog
gener
influenc
outcom
empir
antibiot
treatment
appropri
mdr
pathogen
major
problem
group
patient
clinic
practic
guidelin
summar
follow
risk
factor
mdr
weiskopf
et
al
elderli
person
suffer
varieti
comorbid
associ
factor
predispos
patient
develop
pneumonia
present
tabl
also
multimorbid
associ
death
hospit
return
emerg
depart
within
day
discharg
recent
studi
case
present
least
one
comorbid
accord
age
group
year
old
year
old
year
old
frequent
comorbid
present
chronic
pulmonari
diseas
immunosenesc
elderli
risk
misdiagnosi
delay
diagnosi
frequent
specif
symptom
pulmonari
infect
cough
sputum
fever
chill
chest
pain
may
avail
complaint
must
taken
care
alter
mental
statu
ie
delirium
fall
fatigu
lethargi
delirium
anorexia
tachypnea
tachycardia
less
commonli
pleurit
pain
cough
fever
rockwood
et
al
elderli
pneumonia
sometim
present
exacerb
decompens
previou
comorbid
also
case
radiograph
find
inconclus
difficult
interpret
mani
biomark
infect
leukocyt
count
creactiv
protein
crp
procalcitonin
found
play
role
earli
diagnosi
elderli
cap
reliabl
biomark
limit
liu
et
al
patient
screen
puls
oximetri
unsuspect
hypoxemia
patient
diagnos
pneumonia
determin
presenc
pneumonia
without
obviou
sign
sinc
microbiolog
diagnosi
pneumonia
import
better
clinic
outcom
follow
nation
intern
guidelin
recommend
recommend
regard
sampl
diagnost
test
present
tabl
clinic
indic
extens
diagnost
test
decid
clinic
basi
tabl
etiolog
diagnos
import
epidemiolog
implic
agent
report
public
health
offici
vari
accord
countri
gener
legionnair
diseas
sar
sever
acut
respiratori
syndrom
psittacosi
avian
influenza
possibl
agent
bioterror
plagu
tularemia
anthrax
accept
microorgan
notifi
low
mild
case
cap
recommend
microbiolog
diagnost
test
option
case
sever
cap
take
blood
cultur
sputum
stain
sputum
cultur
urinari
antigen
test
legionella
pneumococcu
recommend
main
problem
method
low
yield
long
turnaround
time
h
effect
previou
antibiot
use
microbiolog
result
chastr
fagon
case
hap
microbiolog
test
perform
respiratori
sampl
sampl
obtain
spontan
expector
sputum
induct
nasotrach
suction
endotrach
aspir
patient
requir
mechan
ventil
vap
case
noninvas
sampl
endotrach
aspir
cultur
blood
cultur
recommend
kalil
et
al
blood
pleural
cultur
antimicrobi
treatment
perform
blood
cultur
high
specif
low
posit
less
case
blood
cultur
option
especi
patient
host
defect
exampl
asplenia
complement
defici
chronic
liver
diseas
leukopenia
indic
along
patient
hap
posit
blood
cultur
vari
spread
infect
blood
occur
vap
case
blood
cultur
avail
limit
approxim
cap
case
pleural
effus
patient
pleural
effus
cm
height
later
upright
chest
radiograph
undergo
thoracentesi
empyema
consid
risk
factor
poor
outcom
pleural
fluid
sampl
pneumococc
antigen
molecular
detect
recommend
also
falguera
et
al
sputum
gram
stain
cultur
antimicrobi
therapi
sputum
sampl
collect
perform
diagnost
accuraci
adequ
collect
transport
sampl
recommend
good
qualiti
sampl
consid
sputum
sampl
contain
less
epitheli
cell
lymphocyt
cell
benefit
sputum
gram
stain
broaden
initi
empir
therapi
less
common
etiolog
aureu
gramneg
organ
valid
subsequ
sputum
cultur
result
pneumonia
caus
pneumonia
sensit
gram
stain
aureu
anevlavi
et
al
endotrach
aspir
equival
sputum
vap
case
gram
stain
cultur
endotrach
aspir
recommend
intub
patient
sampl
share
criteria
qualiti
vap
case
distinguish
colon
infect
threshold
coloni
form
unitsml
recommend
cook
mandel
antigen
test
legionella
serotyp
pneumococcu
antigen
renal
excret
detect
sensit
pneumococcu
rang
specif
pneumococc
pneumonia
disadvantag
test
cost
amount
per
specimen
fals
posit
result
children
chronic
respiratori
diseas
colon
pneumonia
navarro
et
al
along
legionella
serogroup
sensit
specif
report
problem
recommend
empir
antibiot
regimen
cover
microorgan
research
necessari
investig
clinic
use
method
rapid
antigen
detect
test
influenza
help
consider
antivir
therapi
although
test
perform
vari
accord
patient
age
test
use
sampl
type
durat
ill
sensit
specif
observ
adult
disadvantag
includ
cost
per
specimen
high
rate
falseneg
result
falseposit
result
adenoviru
superior
accord
physician
judgment
last
year
microbiolog
diagnosi
respiratori
pathogen
molecular
diagnost
test
investig
test
provid
identif
specif
pathogen
differenti
bacteri
viral
infect
antibiot
suscept
respons
antibiot
therapi
assess
prognosi
diseas
surveil
evalu
techniqu
method
approv
food
drug
administr
fda
gadsbi
et
al
approxim
case
remain
without
microbiolog
identif
convent
method
togeth
molecular
test
improv
microbiolog
diagnosi
clinic
manag
case
pneumonia
chest
radiograph
requir
routin
evalu
patient
like
pneumonia
chest
radiograph
sometim
use
suggest
etiolog
agent
altern
diagnos
associ
condit
computer
tomographi
scan
may
sensit
find
radiographi
neg
unclear
patient
hospit
suspect
pneumonia
neg
chest
radiograph
find
advanc
treat
presumpt
antibiot
repeat
imag
h
manag
elderli
patient
present
pneumonia
evalu
sever
siteofcar
decis
critic
elderli
patient
cap
sever
mortal
predictor
report
chronic
comorbid
main
predictor
mortal
readmiss
prognost
valu
glucos
level
investig
markedli
elev
blood
glucos
level
admiss
associ
increas
shortterm
longterm
mortal
anoth
studi
neutrophiltolymphocyt
ratio
evalu
present
better
predict
mortal
accord
pneumonia
sever
index
psi
fine
et
al
lim
et
al
comparison
made
term
mortal
crp
white
blood
cell
wbc
count
index
psi
observ
significantli
associ
mortal
icu
admiss
psi
base
paramet
evalu
time
clinic
present
three
demograph
five
comorbid
condit
five
physic
examin
find
seven
laboratoryimag
variabl
tabl
fine
et
al
primari
purpos
score
distinguish
patient
could
safe
treat
outpati
set
versu
inpati
observ
treatment
major
limit
psi
score
focus
age
comorbid
consid
psychosoci
variabl
infrequ
comorbid
patient
prefer
regard
treatment
less
complex
score
system
requir
six
variabl
evalu
present
tabl
lim
et
al
sever
assess
hospit
decis
use
score
present
tabl
age
extrem
signific
variabl
score
highlight
elderli
patient
pneumonia
risk
higher
sever
diseas
poorer
clinic
outcom
limit
score
contain
data
hypoxemia
electrolyt
disturb
inabl
take
oral
medic
predict
icu
admiss
risk
death
patient
sever
cap
sever
tool
also
design
exampl
includ
smartcop
cappiro
score
guidelinesdexcept
onedinclud
age
one
variabl
associ
poor
outcom
use
age
year
old
one
minor
criterion
determin
sever
ill
smartcop
score
system
evalu
need
respiratori
vasopressor
support
score
age
one
sever
marker
tachypnea
poor
oxygen
use
adjust
tool
rello
colleagu
develop
cappiro
score
score
evalu
predisposit
infect
respons
organ
dysfunct
variabl
espana
et
al
charl
et
al
rello
et
al
detail
inform
score
present
tabl
icu
admiss
anoth
import
medic
decis
patient
direct
admiss
icu
requir
patient
septic
shock
requir
vasopressor
acut
respiratori
failur
requir
intub
mechan
ventil
also
patient
three
minor
criteria
sever
cap
list
tabl
direct
admiss
icu
highlevel
monitor
unit
recommend
must
bear
mind
earli
recognit
sepsi
elderli
compromis
patient
challeng
classic
criteria
defin
system
inflammatori
respons
syndrom
absent
anerg
patient
conclus
addit
object
criteria
age
clinician
experi
clinic
judgment
alway
recommend
proper
evalu
practic
function
order
decid
admit
patient
hospit
idsa
at
guidelin
major
minor
criteria
proper
paramet
admit
patient
icu
antimicrobi
mainstay
treatment
elderli
patient
cap
select
antimicrobi
empir
therapi
base
predict
like
pathogen
knowledg
local
suscept
pattern
unless
outcom
data
clearli
favor
one
drug
recommend
gener
take
place
class
antibiot
overal
efficaci
remain
major
factor
mani
class
agent
factor
like
pharmacokineticspharmacodynam
complianc
safeti
cost
must
consider
common
pathogen
cap
present
tabl
accord
sever
ill
judg
site
care
term
analyz
microbi
etiolog
elderli
cohort
studi
cap
patient
shown
patient
divid
age
microbiolog
diagnosi
possibl
decreas
steadili
age
year
old
year
old
year
older
et
al
age
group
consid
substanti
risk
factor
help
predict
respons
microorgan
final
select
proper
antimicrobi
therapi
tabl
current
intern
guidelin
treatment
cap
specif
recommend
elderli
patient
guidelin
evalu
follow
treatment
patient
take
place
three
categori
outpati
treatment
inpatientnon
icu
treatment
inpati
icu
treatment
recommend
outpati
treatment
list
clinic
risk
previous
healthi
use
antimicrobi
within
previou
month
macrolid
azithromycin
clarithromycin
erythromycin
strong
recommend
doxycyclin
weak
recommend
presenc
comorbid
chronic
heart
lung
liver
renal
diseas
diabet
mellitu
alcohol
malign
asplenia
immunosuppress
condit
use
immunosuppress
drug
use
antimicrobi
within
previou
month
respiratori
fluoroquinolon
moxifloxacin
gemifloxacin
levofloxacin
mg
strong
recommend
point
at
american
thorac
societi
cap
communityacquir
pneumonia
icu
care
unit
idst
infecti
diseas
societi
america
piro
predisposit
infect
respons
organ
dysfunct
score
ps
ph
systol
blood
pressur
confus
urea
nitrogen
respiratori
rate
xray
find
oxygen
arteri
pressur
age
year
smartcop
systol
blood
pressur
multilobar
chest
radiographi
albumin
level
respiratori
rate
tachycardia
confus
oxygen
ph
bun
blood
urea
nitrogen
wbc
white
blood
cell
blactam
plu
macrolid
highdos
amoxicillin
eg
g
three
time
daili
amoxicillinclavulan
g
two
time
daili
prefer
altern
includ
ceftriaxon
cefpodoxim
cefuroxim
mg
two
time
daili
doxycyclin
altern
macrolid
strong
recommend
region
high
rate
infect
highlevel
mic
mgml
macrolideresist
pneumonia
consid
use
altern
agent
list
patient
without
comorbid
moder
recommend
recommend
hospit
ward
treatment
list
clinic
risk
respiratori
fluoroquinolon
strong
recommend
blactam
plu
macrolid
strong
recommend
prefer
blactam
agent
includ
cefotaxim
ceftriaxon
ampicillin
ertapenem
select
patient
patient
risk
infect
pathogen
patient
recent
receiv
antibiot
therapi
doxycyclineda
altern
macrolid
respiratori
fluoroquinolon
use
penicillinallerg
patient
hospit
admit
patient
initi
treatment
given
intraven
without
risk
factor
sever
pneumonia
could
receiv
oral
therapi
especi
highli
bioavail
agent
fluoroquinolon
intraven
blactam
combin
coverag
atyp
pathogen
macrolid
doxycyclin
oral
therapi
appropri
select
patient
without
sever
pneumonia
risk
factor
recommend
icu
treatment
list
clinic
risk
minim
recommend
treatment
blactam
cefotaxim
ceftriaxon
ampicillinsulbactam
plu
either
azithromycin
fluoroquinolon
strong
recommend
penicillinallerg
patient
respiratori
fluoroquinolon
aztreonam
common
pathogen
icu
popul
descend
order
frequenc
pneumonia
legionella
speci
h
influenza
enterobacteriacea
speci
aureu
pseudomona
speci
recommend
standard
empir
regimen
routin
cover
three
common
pathogen
atyp
pathogen
relev
enterobacteriacea
speci
treatment
mrsa
p
aeruginosa
infect
modif
standard
empir
regimen
necessari
along
suspicion
pathogen
modif
basic
empir
treatment
pseudomona
infect
use
antipneumococc
antipseudomon
blactam
piperacillintazobactam
cefepim
imipenem
meropenem
plu
either
ciprofloxacin
levofloxacin
dose
blactam
plu
aminoglycosid
azithromycin
blactam
plu
aminoglycosid
antipneumococc
fluoroquinolon
penicillinallerg
patient
substitut
aztreonam
blactam
structur
lung
diseas
bronchiectasi
repeat
chronic
lung
diseas
exacerb
well
prior
antibiot
therapi
clinic
risk
factor
infect
pseudomona
speci
requir
icu
admiss
routin
pathogen
patient
chronic
alcohol
seriou
gramneg
pathogen
k
pneumonia
acinetobact
speci
import
clinic
risk
factor
cap
aureu
includ
endstag
renal
diseas
inject
drug
abus
rapid
present
progress
associ
skin
lesion
prior
influenza
prior
antibiot
therapi
mssa
empir
combin
therapi
recommend
adequ
actual
vancomycin
never
specif
studi
cap
linezolid
detect
superior
vancomycin
retrospect
analysi
nosocomi
mrsa
pneumonia
newer
present
avail
agent
daptomycin
use
cap
tigecyclin
avail
data
pathogendirect
therapi
etiolog
cap
identifi
reliabl
microbiolog
method
antimicrobi
therapi
orient
pathogen
moder
recommend
benefit
combin
therapi
also
pronounc
sever
ill
patient
result
cultur
discontinu
combin
therapi
like
safe
nonicu
patient
et
al
earli
treatment
within
h
onset
symptom
oseltamivir
zanamivir
recommend
influenza
strong
recommend
oseltamivir
zanamivir
recommend
patient
uncompl
influenza
symptom
h
drug
may
use
reduc
viral
shed
hospit
patient
influenza
pneumonia
moder
recommend
parenter
acyclovir
indic
varicella
zoster
herp
simplex
viru
pneumonia
antivir
treatment
proven
valu
avail
viral
type
pneumonia
increas
greater
observ
enterobacteriacea
esbl
especi
patient
recent
hospit
elderli
ertapenem
good
therapeut
option
good
sensit
patient
switch
intraven
oral
therapi
hemodynam
stabl
abl
ingest
medic
normal
function
gastrointestin
tract
strong
recommend
patient
discharg
soon
clinic
stabl
inpati
observ
receiv
oral
therapi
necessari
moder
recommend
patient
higher
psi
risk
score
take
longer
reach
clinic
stabil
patient
lower
risk
elderli
patient
multipl
comorbid
gener
recov
slowli
appropri
followup
rehabilit
plan
initi
earli
patient
elderli
present
delirium
resolut
may
repres
clinic
marker
improv
patient
cap
treat
minimum
day
afebril
h
clinic
instabl
sign
one
discontinu
therapi
moder
recommend
water
et
al
ramirez
et
al
initi
therapi
activ
identifi
pathogen
complic
extrapulmonari
infect
longer
durat
therapi
may
need
weak
recommend
criteria
clinic
stabil
present
tabl
arnold
et
al
patient
cap
treat
day
longer
wellcontrol
studi
evalu
optim
durat
therapi
shortdur
may
suboptim
patient
bacterem
aureu
pseudomona
infect
presenc
caviti
sign
tissu
necrosi
may
requir
prolong
treatment
import
treatment
consider
patient
cap
along
persist
septic
shock
despit
adequ
fluid
resuscit
evalu
therapi
drotrecogin
alfa
activ
within
h
admiss
weak
recommend
dadvic
patient
group
patient
septic
shock
sepsisinduc
leukopenia
organ
failur
criteria
hypotens
fluidresuscit
patient
sever
cap
screen
adren
insuffici
moder
recommend
stressdos
mg
hydrocortison
per
day
equival
steroid
treatment
improv
outcom
vasopressordepend
patient
septic
shock
document
inadequ
cortisol
level
patient
hypoxemia
respiratori
distress
receiv
cautiou
trial
noninvas
ventil
niv
unless
requir
immedi
intub
moder
recommend
lowtidalvolum
ventil
cm
kg
ideal
bodi
weight
use
patient
undergo
ventil
diffus
bilater
pneumonia
ard
strong
recommend
manag
protocol
sever
sepsi
septic
shock
patient
cap
appear
differ
patient
infect
advic
manag
nonrespond
pneumonia
hospit
patient
cap
respond
initi
antibiot
therapi
mortal
among
nonrespond
patient
increas
severalfold
accord
respond
patient
use
systemat
classif
possibl
caus
recommend
tabl
moder
recommend
two
pattern
undesir
respons
seen
hospit
patient
first
progress
pneumonia
clinic
deterior
acut
respiratori
failur
requir
ventilatori
support
andor
septic
shock
within
first
h
hospit
admiss
second
pattern
persist
nonrespond
pneumonia
nonrespond
antibiot
gener
result
three
pattern
clinic
approach
transfer
patient
higher
level
care
diagnost
test
chang
treatment
firstli
patient
nonrespond
deterior
reevalu
initi
microbiolog
result
histori
risk
factor
infect
unusu
pathogen
blood
cultur
repeat
patient
cap
etiolog
determin
bronchoscopi
rapid
urinari
antigen
test
remain
posit
day
initi
antibiot
consid
nonrespond
patient
also
concomit
subsequ
extrapulmonari
infect
intravascular
cathet
urinari
abdomin
skin
infect
must
kept
mind
test
select
patient
nonrespons
chest
ct
bronchoscopi
lavag
transbronchi
biopsi
thoracentesi
current
intern
guidelin
cap
provid
specif
recommend
elderli
patient
conveni
guidelin
associ
shorter
time
clinic
stabil
shorter
length
hospit
stay
lower
inhospit
mortal
egger
et
al
intern
multicent
observ
studi
elderli
patient
report
adher
idsaat
guidelin
hospit
nonicu
elderli
patient
costeffect
costeffect
strategi
icu
patient
faverio
et
al
elderli
patient
anoth
import
issu
agerel
chang
antibiot
therapi
modifi
toler
metabol
excret
drug
risk
drugdrug
interact
case
qt
prolong
concomit
medic
prolong
qt
use
macrolid
fluoroquinolon
suggest
elderli
achil
tendon
ruptur
report
fluoroquinolon
aminoglycosid
nephro
ototox
must
kept
mind
presenc
degre
renal
andor
hepat
failur
alway
evalu
choos
antibiot
treatment
faverio
et
al
anoth
import
risk
elderli
frequenc
aspir
risk
factor
aspir
pneumonia
age
male
gender
neurolog
impair
parkinson
diseas
lung
diseas
diabet
mellitu
malnutrit
periodont
diseas
poor
oral
hygien
vomit
proven
dysphagia
proton
pump
inhibitor
antipsychot
sed
drug
use
diagnos
challeng
diagnost
tool
fiberopt
endoscop
evalu
swallow
fee
perform
bedsid
common
pathogen
oropharyng
flora
includ
anaerob
gramposit
cocci
gramneg
bacilli
antibiot
indigen
oral
flora
includ
anaerob
administ
swallow
rehabilit
oral
healthcar
manag
initi
percutan
endoscop
gastrostomi
peg
often
perform
prevent
aspir
littl
evid
indic
prevent
pneumonia
headup
posit
degre
mosaprid
gastroprokinet
agent
may
prevent
gastroesophag
regurgit
associ
aspir
angiotensinconvert
enzym
ace
inhibitor
cilostazol
report
effect
prevent
pneumonia
medic
increas
substanc
p
level
airway
plasma
improv
swallow
cough
reflex
prevent
also
anticholinerg
agent
tricycl
antidepress
diuret
select
serotonin
reuptak
inhibitor
caus
dri
mouth
administ
cautious
elderli
patient
pneumonia
develop
cardiac
complic
associ
increas
mortal
risk
even
advanc
age
associ
higher
risk
long
termmort
caus
death
follow
episod
mainli
relat
comorbid
malign
copd
vascular
diseas
cardiovascular
cerebrovascular
event
increas
rehabilit
nutrit
statu
cap
could
amelior
physic
dysfunct
elderli
effect
pneumococc
polysaccharid
vaccin
prevent
invas
infect
among
elderli
individu
younger
adult
document
epidemiolog
studi
current
two
type
vaccin
avail
polyval
pneumococc
polysaccharid
vaccin
pneumococc
serotyp
includeddand
pneumococc
conjug
vaccin
differ
capsular
polysaccharid
conjug
carrier
protein
enhanc
immunogen
pneumococc
vaccin
year
old
person
receiv
singl
dose
first
follow
dose
year
later
prior
vaccin
age
year
also
receiv
dose
yet
receiv
one
dose
given
year
recent
dose
patient
need
repeat
period
administr
new
dose
least
year
sinc
recent
dose
influenza
chemoprophylaxi
use
adjunct
treatment
vaccin
oseltamivir
zanamivir
approv
prophylaxi
may
use
household
exposur
influenza
work
institut
influenza
outbreak
hayden
et
al
prevent
measur
modifi
risk
factor
reduc
cessat
alcohol
consumpt
smoke
cessat
improv
oral
hygien
ensur
good
nutrit
statu
avoid
contact
lower
respiratori
infect
accept
cap
fifth
lead
caus
death
common
caus
death
infecti
diseas
peopl
age
year
pneumonia
still
common
pathogen
elderli
patient
signific
number
risk
factor
associ
higher
risk
mdr
pathogen
establish
support
measur
systemat
evalu
cognit
nutrit
hydrat
includ
function
statu
must
import
part
clinic
examin
antimicrobi
select
elderli
patient
cap
differ
younger
adult
clinic
practic
guidelin
earli
antibiot
administr
strict
adher
regim
recommend
appropri
restrict
intens
care
ventilatori
support
basi
chronolog
age
differ
manag
patient
hap
vap
age
group
longterm
mortal
rate
cap
hospit
realli
high
elderli
popul
prevent
immun
measur
must
improv
vaccin
pneumococcu
influenza
smoke
cessat
program
may
help
decreas
incid
sever
cap
especi
age
group
